The long term goals of the Developmental Core are to solicit and provide funding for novel research? projects of HIV research from our three member institutions (FHI, RTI, UNC) as well as our minority partners? (within the UNC system, such as North Carolina Central University, Pembroke, UNC-Greensboro, etc., and? outside, such as the University of Puerto Rico). We shall conduct objective peer review and assign senior? investigators as mentors to nurture the research, publication and grant submission. In the first year of the? new grant cycle we shall combine $150,000 of CFAR funds with $65,000 of UNC funds to support one to two? year small ($5,000-$20,000) awards in all aspects of HIV research (basic and clinical sciences, translational? research, epidemiology, vaccines, and behavioral research). We shall continue to focus on the ongoing? epidemic in women, minorities, and international communities. In addition to our annual RFP, we shall set? aside funds for directed research on emerging problems identified by Core Directors. Outreach and? education will be accomplished through 1) presentation by Awardees at our weekly conference, 2) annual? visits to HMUs on World AIDS Day with didactic talks for students and faculty and solicitation of collaborative? research projects, 3) our annual HIV Update course for 400 clinicians from the Southeast, 4) our annual? World AIDS Day Symposium at UNC for RTI, UNC and FHI, 5) our annual Community Forum reviewing new? information for clients, and 6) a university-wide course on AIDS attended by 250 annually. Promising? minority junior investigators will be identified and mentored until they have successful independent careers.? Continuous quality improvement will remain a focus consisting of a review of the entire process including? solicitation, review, mentoring and productivity of Awardees.? The CFAR Developmental Core has awarded 85 small grants since its inception, of which 11 are still in? progress or in data analysis. Developmental research has resulted in: 55 outside grants, with six more? currently in review; one patent; 64 papers, with 17 more either in press or under review; one free statistical? package available on-line; and 71 presentations at national and international conferences. Developmental? Awardees have already received a total of over $50,000,000 in subsequent funding.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Ford, Catherine; Chibwesha, Carla J; Winston, Jennifer et al. (2018) Women's decision-making and uptake of services to prevent mother-to-child HIV transmission in Zambia. AIDS Care 30:426-434
Edwards, Jessie K; Cole, Stephen R; Hall, H Irene et al. (2018) Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens. AIDS 32:261-266
Power, Jennifer; Westle, Andrew; Dowsett, Gary W et al. (2018) Perceptions of HIV cure research among people living with HIV in Australia. PLoS One 13:e0202647
Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82
Scheidell, Joy D; Quinn, Kelly; McGorray, Susan P et al. (2018) Childhood traumatic experiences and the association with marijuana and cocaine use in adolescence through adulthood. Addiction 113:44-56
Tang, Weiming; Mao, Jessica; Liu, Chuncheng et al. (2018) Reimagining Health Communication: A Non-Inferiority Randomized Controlled Trial of Crowdsourced intervention in China. Sex Transm Dis :
Evon, D M; Amador, J; Stewart, P et al. (2018) Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther 47:1001-1011
Weber, Michael D; Andrews, Elizabeth; Prince, Heather A et al. (2018) Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women. Antivir Ther 23:495-504
Wang, Cheng; Mollan, Katie R; Hudgens, Michael G et al. (2018) Generalisability of an online randomised controlled trial: an empirical analysis. J Epidemiol Community Health 72:173-178
Garrido, Carolina; Abad-Fernandez, Maria; Tuyishime, Marina et al. (2018) Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo. J Virol 92:

Showing the most recent 10 out of 1688 publications